Abstract
Observed SARS-CoV-2 infections and deaths are low in tropical Africa raising questions about the extent of transmission. We measured SARS-CoV-2 IgG by ELISA in 9,922 blood donors across Kenya and adjusted for sampling bias and test performance. By 1st September 2020, 577 COVID-19 deaths were observed nationwide and seroprevalence was 9.1% (95%CI 7.6-10.8%). Seroprevalence in Nairobi was 22.7% (18.0-27.7%). Although most people remained susceptible, SARS-CoV-2 had spread widely in Kenya with apparently low associated mortality.
Competing Interest Statement
RA, MM, KK and PA are from the Ministry of Health, Government of Kenya. All other authors declare no competing interests.
Funding Statement
This project was funded by the Wellcome Trust (grant numbers 220991/Z/20/Z and 203077/Z/16/Z) the Bill and Melinda Gates Foundation (INV-017547) and by the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039). Sophie Uyoga is funded by DELTAS Africa Initiative [DEL-15-003]. L. Isabella Ochola-Oyier is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z). Ambrose Agweyu is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1). J. Anthony G. Scott is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation. Ifedayo Adetifa is funded by the United Kingdom Medical Research Council and Department For International Development through a African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant 2268427 LSHTM). GMW is supported by a fellowship from the Oak Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research Institute (Protocol SSC 3426). Blood donors gave individual written consent for the use of their samples for research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data shown in the manuscript are available upon request from the corresponding author. De-identified data has been published on the Havard dataverse server.
